Sona Nanotech Inc

Sona Nanotech's Gold Nanorods Pass Critical Endotoxin Testing Ahead of First Human Cancer Trial

8 days ago

• Sona Nanotech has successfully completed bacterial endotoxin testing on its biocompatible gold nanorods, with all samples showing endotoxin levels below detection limits. • The tested gold nanorods will be used in Sona's upcoming first-in-human Early Feasibility study for its Targeted Hyperthermia™ cancer therapy, with patient enrollment expected this summer. • Sona's proprietary CTAB-free gold nanorods eliminate toxicity risks associated with conventional gold nanorod technologies, potentially offering a safer approach for photothermal cancer treatment.

BioVaxys and Sona Nanotech Partner to Develop Novel Cancer Immunotherapy Combining DPX Platform with Gold Nanorod Technology

14 days ago

• BioVaxys Technology and Sona Nanotech have formed a research collaboration to develop innovative cancer therapeutics by combining BioVaxys' DPX immune educating platform with Sona's targeted hyperthermia therapy using gold nanorods. • The joint research will evaluate the immune-stimulatory properties of DPX administered with photothermal cancer therapy, as well as explore DPX as a carrier for neoantigens expressed on tumor cell surfaces following immunotherapy. • Studies will be conducted at Dalhousie University under Sona's CMO Dr. Carman Giacomantonio, with both companies sharing ownership of any novel therapeutic candidates developed through the program.

Medicus Pharma Initiates Phase 2 Study with Fast-Track Potential

3 months ago

• Medicus Pharma has launched a significant Phase 2 clinical trial, marking a crucial milestone in their drug development program. • The company is actively pursuing FDA fast-track designation, which could potentially accelerate the drug's path to market approval. • This development represents a strategic advancement in Medicus Pharma's pipeline, positioning them for expedited regulatory review.

Novel Gold Nanorod Therapy Shows Promise for 'Cold' Tumor Treatment, To Be Presented at Canadian Melanoma Conference

3 months ago

• Sona Nanotech's innovative Targeted Hyperthermia therapy, utilizing biocompatible gold nanorods, demonstrates effectiveness in treating immunogenically 'cold' tumors through controlled heat delivery. • The groundbreaking research will be showcased at the 19th Canadian Melanoma Conference in Vancouver, featuring presentations by the company's Chief Medical Officer and research team. • The therapy works by using infrared light to heat gold nanorods to 42-48°C, potentially enhancing immune response and improving drug delivery while maintaining safety and cost-effectiveness.